Glycated hemoglobin News and Research

RSS

GFT505 demonstrates dose-dependent efficacy on primary endpoint in phase 2 NASH trial

GENFIT, today announces topline results of the phase 2 GOLDEN-505 trial in NASH. Due to the unexpected rate of resolution of NASH in patients randomized to placebo who had early NASH (NAS of 3, placebo response rate>57%), along with the high number of sites for a limited sample size, the study as initially designed did not enable the trial to meet directly the primary endpoint.

27 Mar 2015

Qualcomm Life, AMC Health to accelerate transformation of health care delivery for at-risk patients

Qualcomm Life, Inc., a subsidiary of Qualcomm Incorporated, and AMC Health, a privately held provider of 'real-time' patient management solutions, today announced a collaborative effort to accelerate the transformation of chronic care and population health management by significantly enhancing connectivity and care coordination for at-risk patients, specifically those with heart failure, hypertension, diabetes, asthma or COPD, in a cost-effective manner.

25 Mar 2015

PTS Diagnostics announces launch of PTS Connect Wellness Solution

PTS Diagnostics, the U.S.-based manufacturer of both the CardioChek brand and the A1CNow family of point-of-care diagnostic products, announces the launch of the PTS Connect Wellness Solution. This secure cloud-based solution will empower health screening companies to screen more individuals faster and corporate wellness programs to improve outcomes by encouraging participants to monitor and track activity and progress online.

10 Mar 2015

New study finds that fetus exposed to tobacco smoke faces diabetes risk in adulthood

A fetus exposed to tobacco smoke may be at increased risk for diabetes in adulthood, a new study of adult daughters finds.

9 Mar 2015

Study finds correlation between tests for hemoglobin A1c using finger stick and oral blood

It is estimated that 8.1 million of the 29.1 million Americans living with diabetes are undiagnosed and many who have diabetes have poor glycemic control. Given that each year many Americans visit a dental provider but not a primary care provider, dental visits may be an opportune site for diabetes screening and monitoring glucose control for many at-risk patients.

27 Feb 2015

EKF introduces new diabetic biomarker test – The Stanbio Chemistry GSP LiquiColor® Assay

Glycated Serum Protein bridges the gap in diabetes testing in cases where HbA1c cannot be reliably measured

From EKF Diagnostics 23 Feb 2015

Study: Definitive indicator of diabetes control deceptively high in African-American children

A new study confirms the findings of two earlier LSU Health New Orleans studies that the definitive indicator of diabetes control, the HbA1c, is deceptively high in African-American children.

19 Feb 2015

Large majority of coronary patients fail to meet lifestyle, risk factor targets

The large majority of coronary patients in Europe are failing to achieve their lifestyle, risk factor and therapeutic targets as set out in the latest prevention guidelines.

17 Feb 2015

Isis announces top-line results from ISIS-PTP1B Rx Phase 2 study in type 2 diabetes patients

Isis Pharmaceuticals, Inc. announced today top-line results from a Phase 2 study of ISIS-PTP1B Rx in patients with type 2 diabetes. In the Phase 2 study patients treated with ISIS-PTP1B Rx achieved statistically significant reductions in body weight and hemoglobin A1c (HbA1c).

3 Feb 2015

Study: About one-third of teens, young adults face social barriers to diabetes management

Managing type 1 diabetes is a never-ending task that requires multiple blood glucose tests, carbohydrate calculations and insulin injections or infusions. This constant effort to control the disease is daunting at any age - and it's especially challenging for teens and young adults.

2 Feb 2015

Postprandial glucagon linked to glycaemic control in Type 1 diabetes

Research shows that postprandial glucagon levels increase over time in children with newly diagnosed Type 1 diabetes, and are associated with worsening glycaemic control, suggesting an adjunctive treatment approach.

30 Jan 2015

EKF highlighting heat and humidity compatible POC hemoglobin analyzer at Arab Health 2015

EKF Diagnostics, the global diagnostics company, announces that it will be highlighting the robustness of its new DiaSpect Tm POC hemoglobin analyzer.

From EKF Diagnostics 15 Jan 2015

ARA 290 drug reduces neuropathic pain in type 2 diabetic patients

Molecular Medicine, a peer-reviewed biomedical journal published by the Feinstein Institute Press, published the results of a new study reporting clinically significant pain reduction in type 2 diabetic patients. In an exploratory study conducted by Araim Pharmaceuticals, a biotech company developing novel treatments for chronic diseases, investigators also observed improvements in metabolic control in patients administered ARA 290.

16 Dec 2014

Closed-loop artificial pancreas system improves diabetes management in adolescents

Research shows that the use of an artificial pancreas system helps to compensate for omission and underestimation of insulin boluses in adolescents with Type 1 diabetes.

1 Dec 2014

No added benefit proven for empagliflozin in type 2 diabetes

Empagliflozin (trade name Jardiance) has been approved since May 2014 for adults with type 2 diabetes mellitus in whom diet and exercise alone do not provide adequate glycaemic control.

21 Nov 2014

EKF Molecular Diagnostics to present at AMP annual meeting

EKF, announces that senior executives from EKF Molecular Diagnostics including CEO, Andrew Webb, will be present at the Association for Molecular Pathology.

From EKF Diagnostics 6 Nov 2014

EnteroMedics' CE Mark for Maestro System expanded to include management of Type 2 diabetes mellitus

EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that its CE Mark for the Maestro Rechargeable (RC) System for obesity was expanded to include the management of Type 2 diabetes mellitus through improved glycemic control.

29 Sep 2014

First data from phase 3 study of investigational once-weekly DPP-4 inhibitor for type 2 diabetes presented by MSD

MSD, known as Merck & Co., Inc. (NYSE: MRK) in the United States and Canada, today announced the presentation of the first data from the Phase 3 clinical development programme for omarigliptin, MSD’s investigational treatment for type 2 diabetes.

18 Sep 2014

FDA approves Contrave extended-release tablets for chronic weight management

Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. jointly announced today that the U.S. Food and Drug Administration has approved Contrave® extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition.

11 Sep 2014

Intensive glycaemic control shows ischaemic heart disease benefit

Intensive glucose lowering may significantly reduce the risk of ischaemic heart disease in at-risk middle-aged people with Type 2 diabetes, a post-hoc analysis of the ACCORD trial suggests.

5 Sep 2014